Noticias y eventos

BVI to Launch New SERENITY and SERENITY Toric Premium Monofocal IOLs, Delivering an Extended Range of Vision to More Patients, at the 2024 ESCRS

• Non-diffractive IOLs SERENITY and SERENITY Toric are the second generation of BVI’s original, innovative ISOPURE premium monofocal IOL launched in 2019.
• These IOLs incorporate patented ISOFOCAL optic technology to provide both distance vision and intermediate vision.¹ The ground-breaking double c-loop POD platform is specifically engineered to deliver precise astigmatism correction and stable IOL positioning.²
• These lenses are designed to meet the growing demand for intermediate-optimized IOLs, which are projected to see a 15% CAGR. ³

Waltham, MA, September 3, 2024 – BVI today unveiled its latest innovations: SERENITY and SERENITY Toric premium monofocal IOLs. These non-diffractive, aspheric IOLs are the second generation of BVI’s pioneering ISOPURE family, first introduced in 2019. Utilizing patented ISOFOCAL optic technology to elegantly balance Depth of Focus (DoF) and image quality, these lenses provide far vision equal to a monofocal but with good intermediate vision up to 66 cm.¹

Continuing the IOL Innovation Legacy

Since the launch of ISOPURE in 2019, BVI has remained committed to providing innovative solutions for patients seeking an uncompromised, extended range of vision. The SERENITY series maintains the simplicity of a monofocal IOL while incorporating ISOFOCAL technology to deliver spherical aberration correction across the entire optic diameter and customize the level of spherical aberration per dioptric power.

The SERENITY Toric model benefits significantly from the maneuverability of the double C-loop POD platform. This platform is exclusive to BVI and allows the IOL to be rotated clockwise or counterclockwise to align the cylinder with the axis. For astigmatic patients, the POD platform delivers a toric IOL that remains stable in the capsular bag,² with outcomes accurately predicted by BVI’s toric calculator.

Mr. Sheraz DayaMD FACP FACS FRCS(Ed) FRCOphth (Centre For Sight, UK), one of the first surgeons to implant SERENITY, commented, “It is wonderful to see this Increased range of focus lens (IROF) on the same platform as the Finevision with 4 C loop haptics. I look forward to the Toric version as well which I know will be very stable with no rotation.”

“As we launch the second-generation SERENITY and SERENITY Toric IOLs, BVI views this IOL as potentially a game-changer when it comes to standard of care for monofocal procedures,” saidShervin Korangy, President and CEO of BVI. “Our portfolio includes a wide range of IOLs, meticulously designed from material to haptics to optics to provide the optimal outcome without the burden of retro-fitting legacy predicate devices.”

Global Launch Schedule

SERENITY and SERENITY Toric will have full commercial availability in CE-accepting markets in 2025⁴.

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

For further enquiries or to speak to a BVI representative, please email Andrew Dawson, Head of BVI Corporate Communications: adawson@bvimedical.com

References

1. Bernabeu-Arias G, Beckers S, RincónRosales JL, Tañá-Rivero P, Bilbao-Calabuig R. Visual Performance at Different Distances After Implantation of an Isofocal Optic Design Intraocular Lens. J Refract Surg. 2023 Mar;39(3):150-157.
2. Robert Edward T Ang, Pedro Tañá-Rivero, Francisco Pastor-Pascual, Pavel Stodulka, Manfred Tetz, Isaak Fischinger. Visual and Refractive Outcomes After Bilateral Implantation of a Biconvex Aspheric Toric Monofocal Intraocular with a Double C-Loop Haptic Design. Clinical Ophthalmology 2023:17 2765–2776.
3. 2024 IOL Market Report, Market Scope, P. 188
4. Not Available for Sale in the United States

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest-growing, diversified surgical ophthalmic businesses in the world, announced the acquisition of Medical Mix, a company specializing in the supply of medical devices for ophthalmic surgery across Spain and Portugal.

This strategic move builds on a period of significant momentum for BVI. The company has transformed into a broad manufacturer and supplier of market-leading, innovative solutions that provide an end-to-end range of products for cataract, retinal, and glaucoma diseases. This acquisition is another pivotal step in BVI’s growth trajectory, which began to take form and accelerate since 2018. BVI’s European footprint with direct sales representatives and infrastructure now spans all major western European markets, increasing from only three markets a short 5 years ago.

Shervin Korangy, BVI President and CEO said: “It is an honor and a pleasure to welcome Medical Mix to the BVI team. When Vicente and I began discussions, it was immediately evident that our strategic vision for our industry was incredibly consistent. This shared vision of the future will serve as a rock-solid foundation for our continued success in the market.”

Founded in 1982 and headquartered in Barcelona, Medical Mix is one of the largest providers of surgical ophthalmic products in Spain and Portugal. The robust portfolio is composed mainly of BVI products alongside other prestigious international brands. The company has been built to consistently deliver the highest quality of service alongside its breadth of products which allow it to serve as a trusted partner to surgeons and patients across both countries.

Medical Mix, a longstanding distributor of BVI’s Intraocular Lenses (IOLs) since 2008, consumables since 2012, and equipment since 2019, has been a key partner with BVI products. This acquisition solidifies the enduring partnership, allowing both companies to provide comprehensive ophthalmic solutions to their customers.

Vicente Durán, Medical Mix Founder and President said: “The partnership with BVI is a very exciting next step for us and the market in Spain and Portugal. The business philosophy and approach of BVI makes our combined future very bright, offering the market the best portfolio of innovative products together with the best service tailored to customers’ needs ”

About BVI
BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

For further enquiries or to speak to a BVI representative, please email Andrew Dawson, Head of BVI Corporate Communications: adawson@bvimedical.com

WALTHAM, Mass. — July 18^th, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium.  This results in a sizeable increase in BVI’s intraocular lens (IOL) business capacity, unlocking new growth opportunities and reinforcing the company’s environmental, social, and governance (ESG) leadership.

In line with the company’s commitment to efficiency, sustainability, and compliance, the new facility was designed to optimize delivery and involved a comprehensive process review aimed at increasing yield and efficiency.  BVI also prioritized environmental considerations and implemented various measures to minimize carbon footprint.

Affirming BVI’s commitment to innovation, the facility further enlarged BVI’s integrated IOL research and development (R&D) and manufacturing capabilities.  With a clear focus on delivering pioneering, quality products to patients, the integrated R&D and manufacturing installation promotes seamless collaboration, efficient product development and production, and accelerated time to market.

This strategic investment exemplifies BVI’s commitment to economic growth, technological advancement, and dedication to maintaining industry leadership. As BVI embarks on this exciting journey, the company anticipates significant positive contributions to its financial success and overall economic landscape.

Frederic Jodogne, Head of Operations said: “I see in this newly built state of the art facility a sign of trust in BVI that confirms Liège as a key pillar in IOL R&D and production.  Amazing products, amazing staff, and amazing potential! Each employee can be proud of the journey already accomplished and can see clearly now the path toward a successful future.”

Shervin Korangy, BVI President and CEO said: “I commend our team who drove this significant capital expansion project. Their unwavering commitment to excellence has been instrumental in tripling our IOL production capacity whilst in parallel deploying cutting-edge, proprietary precision molded optics to the highest quality standards.  The combination of our patented, novel optical designs alongside our world-class manufacturing technology creates an elegant and unrivaled outcome. Our IOL expertise has consistently surpassed even my lofty expectations.”

About BVI

BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving the vision of patients. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors. Our trusted brands include Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).

For further enquiries or to speak to a BVI representative, please email Andrew Dawson, Head of BVI Corporate Communications: adawson@bvimedical.com